FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

Search

Syncona Ltd

Suletud

102 3.55

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

98.3

Max

102

Põhinäitajad

By Trading Economics

Sissetulek

-68M

Müük

44M

Kasumimarginaal

-153.576

Töötajad

1,215

EBITDA

-49M

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

13. nov 2025

Turustatistika

By TradingEconomics

Turukapital

602M

Eelmine avamishind

98.45

Eelmine sulgemishind

102

Syncona Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. okt 2025, 23:50 UTC

Kuumad aktsiad

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28. okt 2025, 23:25 UTC

Tulu

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28. okt 2025, 23:18 UTC

Tulu

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28. okt 2025, 22:20 UTC

Tulu

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28. okt 2025, 22:13 UTC

Tulu

Wal-Mart de Mexico Net Profit Falls in 3Q

28. okt 2025, 21:38 UTC

Tulu

Correction to Visa Sales Jump Article

28. okt 2025, 21:17 UTC

Tulu

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28. okt 2025, 21:07 UTC

Tulu

Visa Sales Jump as Consumers Keep Spending -- Update

28. okt 2025, 21:02 UTC

Tulu

Mondelez Tempers Outlook as Costs Rise

28. okt 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28. okt 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28. okt 2025, 23:02 UTC

Tulu

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28. okt 2025, 23:01 UTC

Tulu

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28. okt 2025, 22:46 UTC

Tulu

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28. okt 2025, 22:45 UTC

Tulu

SK Hynix 3Q Net KRW12.6T >000660.SE

28. okt 2025, 22:44 UTC

Tulu

SK Hynix 3Q Rev KRW24.44T >000660.SE

28. okt 2025, 22:43 UTC

Tulu

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28. okt 2025, 22:42 UTC

Tulu

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28. okt 2025, 22:40 UTC

Tulu

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28. okt 2025, 22:40 UTC

Tulu

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28. okt 2025, 22:20 UTC

Tulu

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28. okt 2025, 22:02 UTC

Tulu

Review & Preview: Earnings Extravaganza -- Barrons.com

28. okt 2025, 21:42 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

28. okt 2025, 21:42 UTC

Market Talk
Tulu

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28. okt 2025, 21:20 UTC

Tulu

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28. okt 2025, 21:19 UTC

Tulu

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28. okt 2025, 21:18 UTC

Tulu

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Võrdlus sarnastega

Hinnamuutus

Syncona Ltd Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

0

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

$

Ettevõttest Syncona Ltd

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
help-icon Live chat